Autoimmune manifestations recorded after SARS-CoV-2 vaccination

Area of Science:

• Immunology
• Vaccinology
• Clinical Medicine

Background:

• Autoimmune manifestations (AIM) following coronavirus disease 2019 (COVID-19) vaccination are increasingly reported.
• Understanding these associations is crucial for vaccine safety monitoring and patient management.

Purpose of the Study:

• To present the largest African case series of autoimmune manifestations after COVID-19 vaccination.
• To investigate the clinical and immunological characteristics of these post-vaccination events.

Main Methods:

• A consecutive case series of 14 patients who developed AIM post-COVID-19 vaccination was collected between March 2021 and December 2022.
• Immunological investigations included anti-nuclear antibody (ANA) screening and autoantibody typing using indirect immunofluorescence, ELISA, and line-blot assays.

Main Results:

• Thirteen out of 14 patients tested positive for ANA, with specific autoantibodies identified including anti-mitochondria type 2, anti-SSA, and anti-DFS70.
• Clinical presentations varied, with some patients diagnosed with autoimmune diseases requiring specific treatment, while others experienced non-specific immune stimulation or related conditions.

Conclusions:

• This case series suggests a potential link between COVID-19 vaccination and the triggering or revealing of autoimmune diseases or manifestations.
• Further research is warranted to elucidate the mechanisms and confirm the association between COVID-19 vaccines and autoimmune conditions.